Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan-Reference-Cited by-同舟云学术

Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan

Published:2018 Issue:3 Volume:65 Page:359-371
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Naruse Mitsuhide¹,Satoh Fumitoshi²,Tanabe Akiyo³,Okamoto Takahiro⁴,Ichihara Atsuhiro⁵,Tsuiki Mika⁶,Katabami Takuyuki⁷,Nomura Masatoshi⁸,Tanaka Tomoaki⁹,Matsuda Tadashi¹⁰,Imai Tsuneo¹¹,Yamada Masanobu¹²,Harada Tomohiro¹³,Kawata Nobuyuki¹³,Takekoshi Kazuhiro¹⁴

Affiliation:

1. Clinical Research Institute for Endocrinology and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan

2. Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan

3. Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

4. Department of Surgery II, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

5. Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

6. Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan

7. Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama 241-0811, Japan

8. Department of Endocrine and Metabolic Diseases, Kyushu University Hospital, Fukuoka 812-8582, Japan

9. Department of Molecular Diagnosis, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

10. Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata 573-1191, Japan

11. National Hospital Organization, Higashinagoya National Hospital, Nagoya 465-8620, Japan

12. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan

13. Ono Pharmaceutical Co., Ltd., Osaka 541-8564, Japan

14. Faculty of Medicine, University of Tsukuba, Tsukuba 305-8577, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/65/3/65_EJ17-0276/_pdf

Reference24 articles.

1. 1 Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366: 665–675.

2. 2 Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, et al. (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39: 775–783.

3. 3 Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405–414.

4. 4 NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 2.2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 15 2017.

5. 5 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, et al. (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 1915–1942.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adrenalectomy for pheochromocytoma: Surgical outcomes and preoperative risk factors for hemodynamic instability;International Journal of Urology;2024-07-15

2. Feocromocitomas y paragangliomas;EMC - Tratado de Medicina;2024-06

3. Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease;International Journal of Molecular Sciences;2024-04-24

4. Tumor metabolism in pheochromocytomas: clinical and therapeutic implications;Exploration of Targeted Anti-tumor Therapy;2024-04-24

5. Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma;The Lancet;2024-03